These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation. Cambruzzi E Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169 [TBL] [Abstract][Full Text] [Related]
9. Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma. Al-Halabi H; Nantel A; Klekner A; Guiot MC; Albrecht S; Hauser P; Garami M; Bognar L; Kavan P; Gerges N; Shirinian M; Roberge D; Muanza T; Jabado N Acta Neuropathol; 2011 Feb; 121(2):229-39. PubMed ID: 21107850 [TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy. Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704 [TBL] [Abstract][Full Text] [Related]
11. Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation. Chen Z; Ioris RM; Richardson S; Van Ess AN; Vendrell I; Kessler BM; Buffa FM; Busino L; Clifford SC; Bullock AN; D'Angiolella V Cell Death Differ; 2022 Oct; 29(10):1955-1969. PubMed ID: 35379950 [TBL] [Abstract][Full Text] [Related]
12. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes. Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271 [TBL] [Abstract][Full Text] [Related]
13. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951 [TBL] [Abstract][Full Text] [Related]
14. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts. Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208 [TBL] [Abstract][Full Text] [Related]
15. A CTNNB1-altered medulloblastoma shows the immunophenotypic, DNA methylation and transcriptomic profiles of SHH-activated, and not WNT-activated, medulloblastoma. Chiang J; Moreira DC; Pytel NJ; Liu YC; Blackburn PR; Shi Z; Cardenas M; Wheeler DA; Furtado LV Neuropathol Appl Neurobiol; 2022 Aug; 48(5):e12815. PubMed ID: 35320876 [TBL] [Abstract][Full Text] [Related]
16. Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas. Menyhárt O; Győrffy B Ann Clin Transl Neurol; 2019 May; 6(5):990-1005. PubMed ID: 31139698 [TBL] [Abstract][Full Text] [Related]
17. Molecular subgroups of adult medulloblastoma: a long-term single-institution study. Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407 [TBL] [Abstract][Full Text] [Related]
18. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma. Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958 [TBL] [Abstract][Full Text] [Related]
19. Subgroup and subtype-specific outcomes in adult medulloblastoma. Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497 [TBL] [Abstract][Full Text] [Related]
20. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]